0.90Open1.00Pre Close2 Volume701 Open Interest11.00Strike Price180.00Turnover119.54%IV19.00%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.90Extrinsic Value100Contract SizeAmericanOptions Type0.4372Delta0.1312Gamma12.12Leverage Ratio-0.0264Theta0.0022Rho5.30Eff Leverage0.0099Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet